Subtype
Malignant Urinary System Neoplasm
CI-CAN-00001187Explore in graph →
888 active trials28 approved drugs109 evidence items
- NCIt
- C9297
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001187Explore in graph →
Clinical trials
3,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (556)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00627432 | Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer | completed | Phase 2 | 44 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT00583349 | Intravesicular Abraxane for Treatment-Refractory Bladder Cancer | completed | Phase 1 / Phase 2 | 46 | Columbia UniversityOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06829888 | Percutaneous Tumor Ablation Vs Partial Nephrectomy for Small Renal Mass: the Impact of Histologic Variant and Tumor Size(CRYO-BO-2021) | completed | — | 955 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 0 | Feb 17, 2025 | clinicaltrials |
| NCT04043975 | A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan | completed | — | 286 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04666688 | LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 44 | PureTechINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06818799 | Thulium Laser En-bloc Resection of Primary Non-muscle Invasive Bladder Cancer | completed | N/A | 50 | Helwan UniversityOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT01489813 | Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment | completed | Phase 2 | 36 | Emory UniversityOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT04492007 | Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS)(PRISMS) | completed | N/A | 46 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT01697306 | The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer | completed | Phase 2 | 120 | A.O.U. Città della Salute e della ScienzaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT03473730 | Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer | completed | Early Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06796413 | Loop Resection or Cold-cup Biopsy? A Study Comparing the Accuracy of Muscle Samples During Bladder Tumor Surgery | completed | N/A | 120 | University of StellenboschOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT02662062 | Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer(PCR-MIB) | completed | Phase 2 | 28 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT03523572 | Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer | completed | Phase 1 | 86 | Daiichi SankyoINDUSTRY | 7 | Jan 27, 2025 | clinicaltrials |
| NCT03154190 | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | completed | N/A | 128 | Stanford UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06791863 | Visceral Fat Area as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma: A Multicenter Study on Postoperative Survival | completed | — | 1,030 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06789224 | Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device(REMOVE) | completed | N/A | 136 | Lindis Bloodcare GmbHINDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT03240016 | Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer(ABLE) | completed | Phase 2 | 36 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06778538 | Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients(HPGD-ccRCC) | completed | — | 40 | Shang PanfengOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06775574 | Prognostic Significance of the Lung Immune Prognostic Index (LIPI) in Postoperative Clear Cell Renal Cell Carcinoma: a Multicenter Retrospective Cohort Study | completed | — | 704 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT01884961 | Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2(IL2HD) | completed | Phase 2 | 46 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT02761057 | Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed | completed | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 2 | Jan 13, 2025 | clinicaltrials |
| NCT06768346 | Hyperthermic Intra-Vesical Chemotherapy(HIVECII) | completed | N/A | 259 | Queen Mary University of LondonOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT05578898 | CLEAR Care Companion Application | completed | N/A | 28 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT04068831 | Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05461027 | Percutaneous Cryoablation of Central Kidney Tumours With Temporary Renal Artery Occlusion(CP-Renal) | completed | — | 16 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04314778 | FITBIT Study on Mobility and Readmissions After Radical Cystectomy(FITBIT) | completed | N/A | 64 | University of PennsylvaniaOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03138512 | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney(CheckMate 914) | completed | Phase 3 | 1,641 | Bristol-Myers SquibbINDUSTRY | 25 | Dec 18, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04957160 | Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination(CARINA) | completed | — | 281 | IpsenINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT05939856 | Lymph Node Dissection Before or After Cystectomy(LBOACP) | completed | N/A | 50 | Jagiellonian UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04806178 | Immunological Response of Bladder Cancer Patients Under BCG(IMMUNOBCG) | completed | Phase 3 | 30 | University of Campinas, BrazilOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05522257 | PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell Carcinomas | completed | N/A | 25 | Leiden University Medical CenterOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01224665 | S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer | completed | N/A | 658 | SWOG Cancer Research NetworkNETWORK | 2 | Nov 29, 2024 | clinicaltrials |
| NCT03534804 | Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma(PemCab) | completed | Phase 2 | 37 | University of UtahOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT02926053 | TIL Therapy for Metastatic Renal Cell Carcinoma | completed | Phase 1 | 5 | Inge Marie SvaneOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT03015740 | Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02619253 | Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma | completed | Phase 1 | 52 | Nabil AdraOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT02639182 | A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma | completed | Phase 2 | 133 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Nov 18, 2024 | clinicaltrials |
| NCT06688643 | The Impact of Intrathecal Morphine Versus Continuous Epidural Analgesia on Return of Bowel Function in Patients Undergoing Laparoscopic Ileal Conduit | completed | N/A | 58 | Xiaguang DuanOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT04036877 | Mood Disorders Bladder Cancer | completed | — | 358 | University of Kansas Medical CenterOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT01627197 | Adjuvant Intraarterial Chemotherapy Following Surgery to Treat Locally Advanced Bladder Cancer | completed | Phase 3 | 186 | Sun Yat-sen UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT03658304 | Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma | completed | Phase 2 | 29 | University of FloridaOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04504669 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | completed | Phase 1 | 60 | AstraZenecaINDUSTRY | 4 | Nov 5, 2024 | clinicaltrials |
| NCT02819596 | MEDI4736 Combinations in Metastatic Renal Cell Carcinoma(CALYPSO) | completed | Phase 2 | 69 | Queen Mary University of LondonOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT01672775 | A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology | completed | Phase 1 | 34 | Agensys, Inc.INDUSTRY | 2 | Nov 1, 2024 | clinicaltrials |
| NCT06656039 | A Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma | completed | — | 1,200 | RenJi HospitalOTHER | 1 | Oct 24, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 18, 2025source: clinicaltrials